Publicaciones en colaboración con investigadores/as de Helmholtz Zentrum München (14)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2022

  1. Immune response differs between intralymphatic or subcutaneous administration of GAD-alum in individuals with recent onset type 1 diabetes

    Diabetes/Metabolism Research and Reviews, Vol. 38, Núm. 3

2021

  1. O-GlcNAcylated p53 in the liver modulates hepatic glucose production

    Nature Communications, Vol. 12, Núm. 1

2020

  1. Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma

    PLoS ONE, Vol. 15, Núm. 9 September

  2. Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020

    International Archives of Allergy and Immunology, Vol. 181, Núm. 5, pp. 321-333

2018

  1. Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility

    Nature Communications, Vol. 9, Núm. 1

2016

  1. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

    Science Translational Medicine, Vol. 8, Núm. 341

  2. T-and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates

    Gene Therapy, Vol. 23, Núm. 10, pp. 753-759

2014

  1. Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration

    Acta Neuropathologica, Vol. 128, Núm. 3, pp. 397-410

2012

  1. Research needs in allergy: An EAACI position paper, in collaboration with EFA

    Clinical and Translational Allergy, Vol. 2, Núm. 1

2011

  1. Defining the critical hurdles in cancer immunotherapy

    Journal of Translational Medicine

2008

  1. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model

    Journal of Gene Medicine, Vol. 10, Núm. 2, pp. 177-186

2007

  1. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity

    Hepatology, Vol. 45, Núm. 3, pp. 602-613